

1 **Title:** Identification of SARS-CoV-2 RNA in Healthcare Heating, Ventilation, and Air  
2 Conditioning Units

3

4 **Working Title:** SARS-CoV-2 in Healthcare HVAC Systems

5

6 **Authors:** Patrick F. Horve<sup>1,\*</sup>, Leslie Dietz<sup>1</sup>, Mark Fretz<sup>2</sup>, David A. Constant<sup>3</sup>, Andrew Wilkes<sup>4</sup>,  
7 John M. Townes<sup>5</sup>, Robert G. Martindale<sup>6</sup>, William B. Messer<sup>3</sup>, Kevin G. Van Den  
8 Wymelenberg<sup>1,2,\*</sup>

9

10 **Affiliations:**

11 <sup>1</sup> Biology and the Built Environment Center, University of Oregon, Eugene, Oregon, USA

12 <sup>2</sup> Institute for Health in the Built Environment, University of Oregon, Portland, Oregon, USA

13 <sup>3</sup> Department of Molecular Microbiology and Immunology, Oregon Health and Science  
14 University, Portland, Oregon, USA

15 <sup>4</sup> Healthcare Facilities, Oregon Health and Science University, Portland, Oregon, USA

16 <sup>5</sup> Division of Infectious Diseases, Department of Medicine, School of Medicine, Oregon Health  
17 and Science University, Portland, Oregon, USA

18 <sup>6</sup> Division of Gastrointestinal and General Surgery, School of Medicine, Oregon Health and  
19 Science University, Portland, Oregon, USA

20

21 **Corresponding Author(s):**

22 \* Kevin Van Den Wymelenberg, kevinvdw@uoregon.edu, (541) 346-5647, Biology and the Built  
23 Environment Center, University of Oregon, 5231 University of Oregon, Eugene, OR, 97403-

24 5231

25 \* Patrick Finn Horve, pfh@uoregon.edu, (541)346-5647, Biology and the Built Environment  
26 Center, University of Oregon, 5231 University of Oregon, Eugene, OR, 97403-5231

27

28 **Author Contributions:** PFH, LGD, MF, and KVDW conceived of the project scope and MF,  
29 JMT, RGM, WBM, and KVDW oversaw project and manuscript development. AW provided  
30 significant technical knowledge and access to hospital HVAC systems and air handling units.  
31 PFH, LD, and DAC performed sample collection, and initial processing. PFH and LD performed  
32 sample transport, nucleic acid isolation, and nucleic acid analysis. PFH performed analysis of  
33 raw abundance data and contributed to figure production. MF and AW developed Figure 1. PFH  
34 and LD wrote the initial manuscript and KVDW, MF, JMT, WBM, DAC, RGM, and AW  
35 provided significant edits to the manuscript.

36

37 **Keywords:** SARS-CoV-2, COVID-19, HVAC, Healthcare, MERV, Filtration, Aerosols

38

39

40

41

42

43

44

45

46

47

48 **Abstract:**

49 Available information on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  
50 transmission by small particle aerosols continues to evolve rapidly. To assess the potential role  
51 of heating, ventilation, and air conditioning (HVAC) systems in airborne viral transmission, this  
52 study sought to determine the viral presence, if any, on air handling units in a healthcare setting  
53 where Coronavirus Disease 2019 (COVID-19) patients were being treated. The presence of  
54 SARS-CoV-2 RNA was detected in approximately 25% of samples taken from nine different  
55 locations in multiple air handlers. While samples were not evaluated for viral infectivity, the  
56 presence of viral RNA in air handlers raises the possibility that viral particles can enter and travel  
57 within the air handling system of a hospital, from room return air through high efficiency  
58 MERV-15 filters and into supply air ducts. Although no known transmission events were  
59 determined to be associated with these specimens, the findings suggest the potential for HVAC  
60 systems to facilitate transmission by environmental contamination via shared air volumes with  
61 locations remote from areas where infected persons reside. More work is needed to further  
62 evaluate the risk of SARS-CoV-2 transmission via HVAC systems and to verify effectiveness of  
63 building operations mitigation strategies for the protection of building occupants. These results  
64 are important within and outside of healthcare settings and may present a matter of some urgency  
65 for building operators of facilities that are not equipped with high-efficiency filtration.

66

67

68

69

70

## 71 **Introduction**

72 Since its emergence in late 2019, SARS-CoV-2 has spread across the globe and led to the deaths  
73 of over 450,000 individuals<sup>1</sup>. The main mechanism of transmission has been identified as  
74 respiratory droplet transmission by symptomatic or asymptomatic persons<sup>2-6</sup>. Despite the  
75 identification of droplet spread as the most common mechanism of transmission<sup>6</sup>, recent studies  
76 suggest that air movement patterns indoors induced through heating, ventilation, and air  
77 conditioning (HVAC) systems may contribute to transmission events<sup>7,8</sup>.

78

79 Aerosolized SARS-CoV-2 RNA has been previously detected in the air of hospital rooms with  
80 symptomatic COVID-19 patients<sup>9-11</sup>, suggesting the possibility that SARS-CoV-2 viral RNA  
81 (and potentially virus) have the capacity to enter into building HVAC systems in evacuated room  
82 air after a shedding or aerosolization event from infected individuals. Although hospitals contain  
83 higher levels of mechanical filtration and room air exchange than almost all other buildings,  
84 which are important strategies to help prevent the transmission of disease, a growing body of  
85 evidence suggests that these precautions may not be adequate to completely eliminate SARS-  
86 CoV-2<sup>12-14</sup> in filtered air. Studies have shown the persistence of SARS-CoV-2 in air to be hours  
87 and on surfaces, days<sup>15</sup>. Efforts to limit the transmission and continued spread of SARS-CoV-2  
88 have mainly focused on social (spatial) distancing, increased cleaning regimens, mandated face  
89 coverings, and increased surveillance<sup>15,16</sup>. However, as more indoor spaces begin to reopen and  
90 increase in occupant density, more individuals will occupy shared air spaces serviced by HVAC  
91 units for extended periods of time. Without an understanding of the risk posed from recirculated  
92 air in these indoor environments, there are potential gaps in the prevention and mitigation plans

93 aimed to reduce SARS-CoV-2 transmission and thereby the number of COVID-19 cases.

94

95 In the past, ventilation has played a key role in the transmission of infectious disease<sup>8,17-19</sup>. With

96 the demonstration that ventilation systems may contribute to occupant transmission events,

97 HVAC and ventilation guidelines and recommendations have been modified<sup>20,21</sup>. As the

98 knowledge regarding ventilation during the SARS-CoV-2 pandemic continues to expand, it is

99 likely that building operations best practices will continue to be updated in response to that body

100 of knowledge. Here, we present data demonstrating the presence of SARS-CoV-2 RNA at

101 several locations along mechanical ventilation air return and supply pathways, including multiple

102 locations in air handling units (AHUs).

103

## 104 **Materials and Methods**

### 105 *Sample Collection*

106 Samples were collected from Oregon Health and Science University (OHSU) hospital in

107 Portland, Oregon, USA on four sampling days in May and June 2020. Environmental sampling

108 does not require Institutional Review Board (IRB) approval; however, the project was reviewed

109 by the OHSU IRB and an IRB Exemption was granted for this work.

110

111 During May and June 2020, samples were collected from three separate AHUs (Figure 1a).

112 Within each AHU, three areas along the path of airflow were sampled, including the pre-filters,

113 final filters, and supply air dampers (Figure 1b). The pre-filters are rated at MERV10 and final

114 filters are rated at MERV15, both in excess of minimum code requirements<sup>22</sup>. Based upon

115 engineering calculations and equipment documentation available, the HVAC system is capable

116 of cycling air from the ward, to the AHU, and back to the ward in a time between 90 seconds and  
117 five minutes, depending on travel distance to room location. Samples were collected using  
118 Puritan PurFlock Ultra swabs (catalog #25-3606-U) and swabs were taken in triplicate at each  
119 AHU location from the left, middle, and right side of each area along the path of airflow. Swabs  
120 were pre-moistened using viral transport media (RMBIO). Swabbing occurred for 20 seconds on  
121 an area approximately 20 X 30 cm at each location and swabs were immediately placed into 15  
122 mL conical tubes (Cole-Parmer, catalog #UX-06336-89) containing 1.5 mL viral transport media  
123 and stored on ice for transport to a BSL-2 laboratory with enhanced precautions (BSL2+) lab for  
124 processing, which typically occurred within two hours after collection. Samples were collected  
125 by the same researcher each sampling time, and the researcher did not demonstrate any  
126 symptoms of COVID-19 and tested negative by qRT-PCR.

127

128 **Figure 1: (a) System diagram of OHSU hospital ventilation supply and return air collected**  
129 **and distributed to multiple floors by sampled AHUs. (b) AHU sectional diagram**  
130 **illustrating the path of airflow, mixing of recirculated return air with outdoor air fraction**  
131 **and locations of swab sampling.**

132

133 *Sample Processing and Molecular Analysis*

134 Samples were hand-carried to a research laboratory at OHSU for initial processing. In a class 2  
135 biosafety cabinet (BSC), conical tubes were vortexed briefly, allowed to settle for five minutes,  
136 and 200  $\mu$ L of the supernatant was removed and combined with 600  $\mu$ L of the lysis/preservative  
137 buffer (DNA/RNA Shield, Zymo Research). Samples were then transported by car to a BSL-2  
138 laboratory at the University of Oregon campus in Eugene, Oregon, USA. Total RNA was

139 extracted from all samples using Zymo Quick-DNA/RNA Viral MagBead kit (Zymo Research  
140 #R2141) and stored at -80°C until analysis. The abundance of SARS-CoV-2 in each sample was  
141 determined using quantitative reverse-transcription polymerase chain reaction (qRT-PCR)  
142 targeting a 157 bp segment of the SARS-CoV-2 spike glycoprotein gene<sup>4</sup>. An artificial gene  
143 standard from Integrated DNA Technologies with known copy number was utilized to create a  
144 dilution series and standard curve for the determination of viral gene copies in each sample<sup>23</sup>,  
145 with a limit of detection of 11.1 gene copies. All qRT-PCR reactions were run in triplicate and  
146 any gene copies observed in no template controls were removed from samples in each plate to  
147 account for interrun variability. Potential contamination during initial processing was assessed  
148 through the use of passive air settling plates and reagent controls within the BSL2 lab. To  
149 accomplish this, passive air settling plates were placed in the BSC and on the outside lab bench  
150 for the duration of processing. Following the completion of specimen processing, the same  
151 swabs, viral transport media, and processing steps were performed in an identical fashion to  
152 environmental samples for the controls. Reagent controls were processed concurrently with  
153 environmental samples. All controls tested negative for the presence of SARS-CoV-2 RNA.

154

## 155 **Results**

156 In total, 56 samples from three different AHUs were collected; 25% (14/56) of samples  
157 contained detectable SARS-CoV-2 RNA (Table S1). The highest abundance sample (~245 gene  
158 copies) was found on the pre-filters, where outside air mixes with recirculated building air. Of  
159 the samples collected, 35% (7/20) of samples at the pre-filters, 16.67% (2/12) of samples at the  
160 final filter, and 20.8% (5/24) of samples at the supply air dampers contained detectable SARS-  
161 CoV-2 RNA (Table 1). The least SARS-CoV-2 RNA was detected at the final filter and the most

162 at the pre-filters (Figure 2).

|                            | Pre-Filters      |                     | Final Filters    |                     | Supply Air Dampers |                     |
|----------------------------|------------------|---------------------|------------------|---------------------|--------------------|---------------------|
|                            | Total Number (n) | Number Positive (%) | Total Number (n) | Number Positive (%) | Total Number (n)   | Number Positive (%) |
|                            | 20               | 7 (35)              | 12               | 2 (16.67)           | 24                 | 5 (20.8)            |
| Cumulative Gene Copies (Σ) | 354.8 (34.2)     |                     | 103.2 (86.2)     |                     | 342.5 (77.7)       |                     |

163

164 **Table 1. Summary statistics and percent of positive samples from each sampling location**

165 **within all AHUs.**

166

167 **Figure 2: Observed total number of SARS-CoV-2 gene copies at the pre-filters (left), final**

168 **filters (middle), and supply air dampers (right).**

169

## 170 Discussion

171 This investigation demonstrates the presence of SARS-CoV-2 RNA at multiple locations within

172 mechanical AHUs, and more specifically, AHUs serving multiple floors of a hospital tower in

173 which COVID-19 patients were housed. Furthermore, SARS-CoV-2 RNA remained detectable

174 33.3% (5/15) of the time at the final sampling location (supply air damper), after the recirculated

175 air had been mixed with fresh outside air, passed through the pre-filter (MERV 10) and final

176 filter (MERV15) stages. This suggests that the filtration practices in place in some of the most

177 highly filtered environments, such as healthcare, does not eliminate the passage of SARS-CoV-2

178 viral RNA, and potentially SARS-CoV-2 viral particles, through HVAC systems and potentially

179 back into the supply air. The infectious potential of this viral genetic material is currently

180 unknown. These data demonstrate the potential that air evacuated from building spaces

181 containing infectious individuals may be recirculated and distributed to other building spaces

182 through centralized HVAC systems while containing SARS-CoV-2 RNA (and possibly virus),



183 even after the filtration process and the dilution from the addition of 70-80% outside air, ( thus,  
184 only 20-30% recirculated air, during the sampling period).

185

186 Although positive samples were not assessed for infectivity of SARS-CoV-2, the presented data  
187 supports previous claims of aerosolized viral particles<sup>8,10-12</sup> that may be carried remotely from  
188 their source by indoor air currents produced by built environment HVAC systems. Despite the  
189 growing evidence of the potential airborne nature of SARS-CoV-2 and the potential for  
190 aerosolized particles to contribute to some transmission events,<sup>6-8,10-12,24,25</sup>, little guidance is  
191 given by both the World Health Organization<sup>26</sup> (WHO) and Centers for Disease Control<sup>27</sup> (CDC)  
192 concerning the potential for viral spread through airborne routes of transmission. The American  
193 Society of Heating Refrigerating and Air-Conditioning Engineers (ASHRAE) Standard 170-  
194 2017 Ventilation for Healthcare Facilities guidelines requires MERV 7 minimum for filter bank  
195 one and MERV 14 minimum for filter bank two in healthcare settings such as those studied  
196 here<sup>22</sup>. The building studied herein exceeds requirements for filtration efficiency at both filter  
197 bank locations. ASHRAE's current Position Document on Infectious Aerosols encourages  
198 consideration of HEPA filtration in healthcare buildings and MERV 13 or higher in non-  
199 healthcare buildings<sup>28</sup>.

200

201 Placement of patients with known or suspected COVID-19 in negative pressure rooms when  
202 available, as recommended by CDC, greatly reduces the risk of re-circulation of virus particles  
203 within HVAC systems. However, most hospitals and outpatient clinics do not have sufficient  
204 numbers of negative pressure rooms to accommodate all patients with known or suspected  
205 COVID-19. Furthermore, a substantial number of infected individuals that are asymptomatic or

206 pre-symptomatic can shed aerosolized viral particles to shared air spaces. This risk of  
207 transmission may be even higher in non-healthcare buildings that often do not have qRT-PCR  
208 based screening practices, and typically have lower air exchange rates and less efficient  
209 filtration, and during extreme weather conditions when HVAC thermal system capacities cannot  
210 manage thermal comfort with higher outside air fractions.

211  
212 Previous studies have demonstrated that SARS-CoV-2 can be found in aerosols and droplets  
213 ranging from 0.25-4 microns<sup>10,11</sup>. In experimentally generated aerosols, SARS-CoV-2 has been  
214 demonstrated to retain infectivity for between one and sixteen hours<sup>29-32</sup>, lending credence to the  
215 potential for aerosolized transmission to occur.

216  
217 There are steps that can be taken to limit the potential impact of airborne dissemination of  
218 viruses in the built environment, including careful donning and doffing of personal protective  
219 equipment<sup>15</sup>, hand hygiene after hand contact with the environment, cleaning of high touch  
220 surfaces, and use of UV radiation<sup>33</sup>. Use of the highest possible efficiency filters for the building  
221 type and HVAC system design<sup>6</sup>, ensuring indoor relative humidity is between 40%-60%<sup>30</sup>, and  
222 increasing the fraction of outside air introduced into indoor environments<sup>6</sup> are additional  
223 strategies that could mitigate transmission of virus through ventilation systems.

224  
225 There were several limitations to this study. First, samples were not evaluated for the presence of  
226 viable SARS-CoV-2 virus. Second, to prevent disruption of hospital operations, routine sampling  
227 of all AHUs was not possible, limiting temporal analysis. Third, the sample point of a filter or  
228 damper can only be representative of that sampling area and the porous nature of the filters may

229 inhibit efficient specimen recovery. Lastly, this is a focused examination of one specific  
230 exposure factor and does not address several others (exposure routes, sampling conditions,  
231 viability) and should therefore only serve as part of the equation in understanding the overall  
232 exposure risk of SARS-CoV-2.

233

## 234 **Conclusion**

235 This study demonstrates SARS-CoV-2 RNA contamination throughout several AHUs path of  
236 flow, including return air, two filtration stages, and supply air, for multiple floors of the hospital  
237 and serves as the first evidence of the potential for SARS-CoV-2 RNA (and possibly virus),  
238 irrespective of viability, to enter into and travel throughout HVAC systems. While there is still a  
239 paucity of information on the potential viability and infectivity of the present SARS-CoV-2, this  
240 paper demonstrates that actions to protect against the potential for SARS-CoV-2 aerosolized  
241 travel, and subsequent transmission, should be taken into account in built environment mitigation  
242 strategies. Specifically, the data suggest that actions should be taken by healthcare facilities  
243 immediately in order to avoid or minimize potential future SARS-CoV-2 healthcare associated  
244 infection given that risks increase as more extreme weather conditions force a reduction in the  
245 outside air admitted to buildings.

246

## 247 **Acknowledgements**

248 The authors would like to thank Oregon Health and Science University for help in collecting  
249 samples from AHUs. The authors would like to thank Georgia MacCrone for her help in  
250 processing samples. The authors would like to thank the University of Oregon Genomics and  
251 Cell Characterization Core Facility (GC3F) for their expertise and resources. The authors would

252 like to thank Flic Coulter and Corinne Fargo from the Messer Laboratory for their contributions  
253 in sample processing and sampling collection method input.

254

## 255 **Funding**

256 This research benefited from the University of Oregon and Oregon Health and Science  
257 University seed research funds and the Oregon Health and Science Foundation.

258

## 259 **References**

260 1. Coronavirus. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed  
261 June 21, 2020.

262 2. Galbadage T, Peterson BM, Gunasekera RS. Does COVID-19 Spread Through Droplets  
263 Alone? *Front Public Health*. 2020;8:163. April 24, 2020.  
264 <http://dx.doi.org/10.3389/fpubh.2020.00163>.

265 3. Miller SL, Nazaroff WW, Jimenez JL, et al. Transmission of SARS-CoV-2 by inhalation of  
266 respiratory aerosol in the Skagit Valley Chorale superspreading event. *Infectious Diseases*  
267 *(except HIV/AIDS)*. June 2020. June 17, 2020.  
268 <https://www.medrxiv.org/content/10.1101/2020.06.15.20132027v2.abstract>.

269 4. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the  
270 2019 novel coronavirus indicating person-to-person transmission: a study of a family  
271 cluster. *Lancet*. 2020;395:514–523. February 15, 2020. [http://dx.doi.org/10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(20)30154-9)  
272 [6736\(20\)30154-9](http://dx.doi.org/10.1016/S0140-6736(20)30154-9).

- 273 5. Modes of transmission of virus causing COVID-19: implications for IPC precaution  
274 recommendations. [https://www.who.int/news-room/commentaries/detail/modes-of-  
276 transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations](https://www.who.int/news-room/commentaries/detail/modes-of-<br/>275 transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations).  
Accessed June 22, 2020.
- 277 6. Allen JG, Marr LC. Recognizing and controlling airborne transmission of SARS-CoV-2  
278 in indoor environments. *Indoor Air*. 2020;30:557–558. 2020.  
279 <http://dx.doi.org/10.1111/ina.12697>.
- 280 7. Shin Young Park, Young-Man Kim, Seonju Yi, et al. Coronavirus Disease Outbreak in Call  
281 Center, South Korea. *Emerging Infectious Disease journal*. 2020;26. 2020.  
282 [https://wwwnc.cdc.gov/eid/article/26/8/20-1274\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-1274_article).
- 283 8. Jianyun Lu, Jieni Gu, Kuibiao Li, et al. COVID-19 Outbreak Associated with Air  
284 Conditioning in Restaurant, Guangzhou, China, 2020. *Emerging Infectious Disease journal*.  
285 2020;26. 2020. [https://wwwnc.cdc.gov/eid/article/26/7/20-0764\\_article](https://wwwnc.cdc.gov/eid/article/26/7/20-0764_article).
- 286 9. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective  
287 Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-  
288 CoV-2) From a Symptomatic Patient. *JAMA*. 2020. 2020.  
289 <http://dx.doi.org/10.1001/jama.2020.3227>.
- 290 10. Santarpia JL, Rivera DN, Herrera V, et al. Transmission Potential of SARS-CoV-2 in Viral  
291 Shedding Observed at the University of Nebraska Medical Center. *Infectious Diseases*  
292 *(except HIV/AIDS)*. March 2020. March 26, 2020.  
293 <https://www.medrxiv.org/content/10.1101/2020.03.23.20039446v2>.

- 294 11. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan  
295 hospitals. *Nature*. April 2020. April 27, 2020. <http://dx.doi.org/10.1038/s41586-020-2271-3>.
- 296 12. Correia G, Rodrigues L, Gameiro da Silva M, Gonçalves T. Airborne route and bad use of  
297 ventilation systems as non-negligible factors in SARS-CoV-2 transmission. *Med*  
298 *Hypotheses*. 2020;141:109781. August 2020.  
299 <http://dx.doi.org/10.1016/j.mehy.2020.109781>.
- 300 13. Singh R. Split Air Conditioners and their role in Airborne Infection Spread: Short  
301 Communication/Research Note. *IndiaRxiv*. April 2020. April 7, 2020.  
302 <https://indiarxiv.org/jp9te/download?format=pdf>.
- 303 14. Dai H, Zhao B. Association of infected probability of COVID-19 with ventilation rates in  
304 confined spaces: a Wells-Riley equation based investigation. *Emergency Medicine*. April  
305 2020. April 24, 2020. <http://dx.doi.org/10.1101/2020.04.21.20072397>.
- 306 15. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the  
307 dominant route for the spread of COVID-19. *Proc Natl Acad Sci U S A*. June 2020. June 11,  
308 2020. <http://dx.doi.org/10.1073/pnas.2009637117>.
- 309 16. Fantini MP, Reno C, Biserni GB, Savoia E, Lanari M. COVID-19 and the re-opening of  
310 schools: a policy maker's dilemma. *Italian Journal of Pediatrics*. 2020;46. 2020.  
311 <http://dx.doi.org/10.1186/s13052-020-00844-1>.
- 312 17. Qian H, Zheng X. Ventilation control for airborne transmission of human exhaled bio-  
313 aerosols in buildings. *J Thorac Dis*. 2018;10:S2295–S2304. July 2018.  
314 <http://dx.doi.org/10.21037/jtd.2018.01.24>.

- 315 18. Menzies D, Fanning A, Yuan L, FitzGerald JM. Hospital ventilation and risk for  
316 tuberculous infection in canadian health care workers. Canadian Collaborative Group in  
317 Nosocomial Transmission of TB. *Ann Intern Med.* 2000;133:779–789. November 21, 2000.  
318 <http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00010>.
- 319 19. Lutz BD, Jin J, Rinaldi MG, Wickes BL, Huycke MM. Outbreak of invasive *Aspergillus*  
320 infection in surgical patients, associated with a contaminated air-handling system. *Clin*  
321 *Infect Dis.* 2003;37:786–793. September 15, 2003. <http://dx.doi.org/10.1086/377537>.
- 322 20. Atkinson J, Chartier Y, Pessoa-Silva CL, Jensen P, Li Y, Seto W-H. *Infection and*  
323 *Ventilation.* World Health Organization; 2009. 2009.  
324 <https://www.ncbi.nlm.nih.gov/books/NBK143278/>. Accessed June 22, 2020.
- 325 21. Schoen BYLJ, E. P, FELLOW/LIFE MEMBER ASHRAE. Guidance for Building  
326 Operations During the COVID-19 Pandemic.  
327 [https://www.uc.edu/content/dam/uc/af/facilities/fme/20%20ASHRAE%20SARS-CoV-](https://www.uc.edu/content/dam/uc/af/facilities/fme/20%20ASHRAE%20SARS-CoV-2%20Guidance.pdf)  
328 [2%20Guidance.pdf](https://www.uc.edu/content/dam/uc/af/facilities/fme/20%20ASHRAE%20SARS-CoV-2%20Guidance.pdf).
- 329 22. ANSI/ASHRAE/ASHE Standard 170-2017, Ventilation of Health Care Facilities.  
330 [https://www.ashrae.org/technical-resources/standards-and-guidelines/standards-](https://www.ashrae.org/technical-resources/standards-and-guidelines/standards-addenda/ansi-ashrae-ashe-standard-170-2017-ventilation-of-health-care-facilities)  
331 [addenda/ansi-ashrae-ashe-standard-170-2017-ventilation-of-health-care-facilities](https://www.ashrae.org/technical-resources/standards-and-guidelines/standards-addenda/ansi-ashrae-ashe-standard-170-2017-ventilation-of-health-care-facilities). Accessed  
332 June 25, 2020.
- 333 23. Fahimipour AK, Hartmann EM, Siemens A, et al. Daylight exposure modulates bacterial  
334 communities associated with household dust. *Microbiome.* 2018;6:175. October 18, 2018.  
335 <http://dx.doi.org/10.1186/s40168-018-0559-4>.

- 336 24. DirkJan Hijnen, Angelo Valerio Marzano, Kilian Eyerich, et al. SARS-CoV-2 Transmission  
337 from Presymptomatic Meeting Attendee, Germany. *Emerging Infectious Disease journal*.  
338 2020;26. 2020. [https://wwwnc.cdc.gov/eid/article/26/8/20-1235\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-1235_article).
- 339 25. Hamner L. High SARS-CoV-2 attack rate following exposure at a choir practice—Skagit  
340 County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69. 2020.  
341 [https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e6.htm?utm\\_medium=email&utm\\_sou](https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e6.htm?utm_medium=email&utm_source=govdelivery)  
342 [rce=govdelivery](https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e6.htm?utm_medium=email&utm_source=govdelivery).
- 343 26. Organization WH, Others. *Infection Prevention and Control during Health Care When*  
344 *COVID-19 Is Suspected: Interim Guidance, 19 March 2020*. World Health Organization;  
345 2020. 2020. [https://apps.who.int/iris/bitstream/handle/10665/331495/WHO-2019-nCoV-](https://apps.who.int/iris/bitstream/handle/10665/331495/WHO-2019-nCoV-IPC-2020.3-eng.pdf)  
346 [IPC-2020.3-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331495/WHO-2019-nCoV-IPC-2020.3-eng.pdf).
- 347 27. CDC. Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment. Centers for  
348 Disease Control and Prevention. June 12, 2020. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html)  
349 [ncov/prevent-getting-sick/prevention.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html). Accessed June 22, 2020.
- 350 28. Stewart EJ, Schoen LJ. The ASHRAE Position Document on Infectious Aerosols was  
351 developed by the Society’s Environmental Health.  
352 [https://www.ashrae.org/file%20library/about/position%20documents/pd\\_infectiousaerosols](https://www.ashrae.org/file%20library/about/position%20documents/pd_infectiousaerosols)  
353 [\\_2020.pdf](https://www.ashrae.org/file%20library/about/position%20documents/pd_infectiousaerosols).
- 354 29. Alyssa C. Fears, William B. Klimstra, Paul Duprex, et al. Persistence of Severe Acute  
355 Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions. *Emerging Infectious Disease*  
356 *journal*. 2020;26. 2020. [https://wwwnc.cdc.gov/eid/article/26/9/20-1806\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-1806_article).



- 357 30. Casanova LM, Jeon S, Rutala WA, Weber DJ, Sobsey MD. Effects of air temperature and  
358 relative humidity on coronavirus survival on surfaces. *Appl Environ Microbiol.*  
359 2010;76:2712–2717. May 2010. <http://dx.doi.org/10.1128/AEM.02291-09>.
- 360 31. Sizun J, Yu MW, Talbot PJ. Survival of human coronaviruses 229E and OC43 in  
361 suspension and after drying on surfaces: a possible source of hospital-acquired infections. *J*  
362 *Hosp Infect.* 2000;46:55–60. September 2000. <http://dx.doi.org/10.1053/jhin.2000.0795>.
- 363 32. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-  
364 CoV-2 as Compared with SARS-CoV-1. *N Engl J Med.* March 2020. March 17, 2020.  
365 <http://dx.doi.org/10.1056/NEJMc2004973>.
- 366 33. Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. Inactivation of severe acute  
367 respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and  
368 ultraviolet light-based photochemical treatment. *Vox Sang.* April 2020. April 20, 2020.  
369 <http://dx.doi.org/10.1111/vox.12937>.



